TY - JOUR
T1 - Predictors of recurrence in the management of chordoid meningioma
AU - Choy, Winward
AU - Ampie, Leonel
AU - Lamano, Jonathan B.
AU - Kesavabhotla, Kartik
AU - Mao, Qinwen
AU - Parsa, Andrew T.
AU - Bloch, Orin
N1 - Publisher Copyright:
© 2015, Springer Science+Business Media New York.
Copyright:
Copyright 2019 Elsevier B.V., All rights reserved.
PY - 2016/1/1
Y1 - 2016/1/1
N2 - Management of chordoid meningiomas (CMs) is complicated by high rates of recurrence, particularly following subtotal resection. Optimal management is not established given the paucity of published experience. To identify prognostic factors for recurrence following resection, the authors conducted the largest systematic review of CMs to date. A comprehensive search on MEDLINE (OVID and Pubmed), Scopus, Embase, and Web of Science utilizing the search terms “chordoid” AND “meningioma” was performed to identify all reports of pathologically confirmed intracranial CMs. A total of 221 patients were included, comprising 120 females and 101 males. Mean age, MIB-1/Ki67, and tumor size was 45.5 years, 4.3 % (range 0.1–26.6 %), and 4.1 cm (range 0.8–10 cm), respectively. 5-, and 10- year progression free survival was 67.5 and 54.4 %, respectively. Gross total resection (GTR) and subtotal resection was achieved in 172 and 48 patients, respectively. Adjuvant radiotherapy (RT) was given to 30 patients. Multivariate analysis found GTR was strongly correlated with decreased recurrence rates (HR 0.04, p = <0.0001), while higher MIB-1 labeling index (≥5 vs <5 %) was associated with increased recurrence (HR 7.08; p = 0.016). Adjuvant RT, age, gender, and tumor location were not associated with recurrence. GTR resection is the strongest predictor of tumor control, and should be the goal to minimize local progression. Additionally, higher MIB-1 labeling was associated with increased rates of tumor recurrence. Tumors that are subtotally resected or demonstrate higher MIB-1 are at greater recurrence and warrant consideration for RT and close long term follow up.
AB - Management of chordoid meningiomas (CMs) is complicated by high rates of recurrence, particularly following subtotal resection. Optimal management is not established given the paucity of published experience. To identify prognostic factors for recurrence following resection, the authors conducted the largest systematic review of CMs to date. A comprehensive search on MEDLINE (OVID and Pubmed), Scopus, Embase, and Web of Science utilizing the search terms “chordoid” AND “meningioma” was performed to identify all reports of pathologically confirmed intracranial CMs. A total of 221 patients were included, comprising 120 females and 101 males. Mean age, MIB-1/Ki67, and tumor size was 45.5 years, 4.3 % (range 0.1–26.6 %), and 4.1 cm (range 0.8–10 cm), respectively. 5-, and 10- year progression free survival was 67.5 and 54.4 %, respectively. Gross total resection (GTR) and subtotal resection was achieved in 172 and 48 patients, respectively. Adjuvant radiotherapy (RT) was given to 30 patients. Multivariate analysis found GTR was strongly correlated with decreased recurrence rates (HR 0.04, p = <0.0001), while higher MIB-1 labeling index (≥5 vs <5 %) was associated with increased recurrence (HR 7.08; p = 0.016). Adjuvant RT, age, gender, and tumor location were not associated with recurrence. GTR resection is the strongest predictor of tumor control, and should be the goal to minimize local progression. Additionally, higher MIB-1 labeling was associated with increased rates of tumor recurrence. Tumors that are subtotally resected or demonstrate higher MIB-1 are at greater recurrence and warrant consideration for RT and close long term follow up.
KW - Atypical
KW - Chordoid
KW - Meningioma
KW - Radiation therapy
KW - Surgery
UR - http://www.scopus.com/inward/record.url?scp=84951569823&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84951569823&partnerID=8YFLogxK
U2 - 10.1007/s11060-015-1940-9
DO - 10.1007/s11060-015-1940-9
M3 - Article
C2 - 26409888
AN - SCOPUS:84951569823
VL - 126
SP - 107
EP - 116
JO - Journal of Neuro-Oncology
JF - Journal of Neuro-Oncology
SN - 0167-594X
IS - 1
ER -